Type 2 Diabetes Mellitus With Sitagliptin Therapeutics
1. Brynovin patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11944621 | AZURITY | Oral gliptin compositions and method for preparation thereof |
Oct, 2040
(14 years from now) | |
| US12295953 | AZURITY | Oral gliptin compositions and method for preparation thereof |
Oct, 2040
(14 years from now) | |
Drugs and Companies using SITAGLIPTIN HYDROCHLORIDE ingredient
Market Authorisation Date: 16 January, 2025
Dosage: SOLUTION
More Information on Dosage
BRYNOVIN family patents
2. Januvia patent expiration
Treatment: Improvement of glycemic control in adults with type 2 diabetes mellitus in combination with metformin.; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor ...
JANUVIA's oppositions filed in EPO
JANUVIA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326708 | MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7459428 | MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(7 years ago) | |
| US7078381 | MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(7 years ago) | |
| US6890898 | MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(7 years ago) | |
| US6699871 | MERCK | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(3 years ago) | |
| US6303661 | MERCK | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(8 years ago) | |
| US7125873 | MERCK | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(3 years ago) | |
|
US6699871 (Pediatric) | MERCK | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(3 years ago) | |
|
US7125873 (Pediatric) | MERCK | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(3 years ago) | |
|
US7326708 (Pediatric) | MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2011 |
| M(M-244) | Aug 12, 2022 |
| M(M-187) | Dec 04, 2023 |
| Pediatric Exclusivity(PED) | Jun 04, 2024 |
Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 05 June, 2023
Market Authorisation Date: 16 October, 2006
Dosage: TABLET
How can I launch a generic of JANUVIA before it's drug patent expiration?
More Information on Dosage
JANUVIA family patents